Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

References

• 2014 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 2014;10(2):e47-92
   PubMed Web of Science ®Google Scholar
• Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80(19):1778-83
   PubMed Web of Science ®Google Scholar
• Hurd MD, Martorell P, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013;369(5):489-90
   PubMedGoogle Scholar
• Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord 2009;2(3):163-80
   PubMedGoogle Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006(1):CD005593
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3(2):211-25
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348(14):1333-41
   PubMed Web of Science ®Google Scholar
• Lin CH, Huang YJ, Lin CJ, et al. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease. Curr Pharm Des 2014;20(32):5169-79
   PubMedGoogle Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar
• Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184(3-4):523-39
   PubMed Web of Science ®Google Scholar
• Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001;49(3):258-67
   PubMed Web of Science ®Google Scholar
• Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol 2013;86(8):1122-32
   PubMed Web of Science ®Google Scholar
• Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007;47:699-729
   PubMed Web of Science ®Google Scholar
• Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 2005;48(15):4705-45
   PubMedGoogle Scholar
• Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006;27(9):482-91
   PubMed Web of Science ®Google Scholar
• Livingstone P, Dickinson J, Srinivasan J, et al. Glutamate–Dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596. J Mol Neurosci 2010;40(1-2):172-6
   PubMedGoogle Scholar
• Vallés AS, Borroni MV, Barrantes FJ. Targeting Brain α7 Nicotinic Acetylcholine Receptors in Alzheimer’s Disease: Rationale and Current Status. CNS Drugs 2014;28(11):975-87
   PubMedGoogle Scholar
• Gotti C, Clementi F, Fornari A, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009;78(7):703-11
   PubMed Web of Science ®Google Scholar
• Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010;6(2):78-87
   PubMed Web of Science ®Google Scholar
• Hernandez CM, Kayed R, Zheng H, et al. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer’s disease. J Neurosci 2010;30(7):2442-53
   PubMedGoogle Scholar
• Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000;61(1):75-111
   PubMed Web of Science ®Google Scholar
• Wang HY, Lee DH, D’Andrea MR, et al. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem 2000;275(8):5626-32
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer’s beta-amyloid fibrils in vitro. Biol Psychiatry 2002;52(9):880-6
   PubMedGoogle Scholar
• Inestrosa NC, Godoy JA, Vargas JY, et al. Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation. Neuromolecular Med 2013;15(3):549-69
   PubMed Web of Science ®Google Scholar
• Kroker KS, Moreth J, Kussmaul L, et al. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitor and selective neuronal nicotinic receptor agonists. Brain Res Bull 2013;96:28-38
   PubMedGoogle Scholar
• Gault L, Ritchie C, Robieson W, et al. Efficacy and safety of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. Alzheimer’s Dementia 2013;9(4 Suppl):P138
   Google Scholar
• Gault LM, Meier A, Florian H, et al. A phase 2 trial of the efficacy and safety of the alpha7 agonist ABT-126 as an add-on treatment in mild-to-moderate Alzheimer’s dementia. Alzheimer’s Dementia 2014;10(4 Suppl):P917-18
   Google Scholar
• Othman A, Meier A, Ritchie CW, et al. Efficacy and safety of the ALPHA7 agonist ABT-126 as a monotherapy treatment in mild-to-moderate Alzheimer’s dementia: results of a phase 2B trial. Alzheimer’s Dementia 2014;10(4 Suppl):P137
   Google Scholar
• Abbvie Inc. Management’s discussion and analysis of financial condition and results of operation. Pharmacy choice. 21 February 2014. Available from: www.pharmacychoice.com/news/article.cfm?Article_ID=1168056 [Last accessed 22 October 2014]
   Google Scholar
• Memory pharmaceuticals announces positive phase 2a results for MEM 3454 in Alzheimer’s disease. Drugs.com. 2 November 2007. Available from: www.drugs.com/clinical_trials/memory-pharmaceuticals-announces-positive-phase-2a-results-mem-3454-alzheimer-s-2538.html [Last accessed 22 October 2014]
   Google Scholar
• A study of RO5313534 as add-on to donepezil treatment in patients with mild to moderate Alzheimer’s disease. ClinicalTrials.gov. 17 April 2009. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00884507 [Last accessed 22 October 2014]
   Google Scholar
• Targacept announces negative top-line results from phase 2b clinical trial of TC-5619 in schizophrenia. BusinessWire. 16 December 2013. Available from: www.businesswire.com/news/home/20131216006281/en/Targacept-Announces-Negative-Top-Line-Results-Phase-2b [Last accessed 22 October 2014]
   Google Scholar
• NeuroPerspective. February 2014. Available from: www.niresearch.com/Images/PDF/NPFebruary2014.pdf [Last accessed 22 October 2014]
   Google Scholar
• Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 2012;62(2):1099-110
   PubMedGoogle Scholar
• Huang M, Felix AR, Flood DG, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl) 2014;231(23):4541-51
   PubMedGoogle Scholar
• Wallace TL, Callahan PM, Tehim A, et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 2011;336(1):242-53
   PubMed Web of Science ®Google Scholar
• Hauser TA, Kucinski A, Jordan KG, et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009;78(7):803-12
   PubMed Web of Science ®Google Scholar
• Malysz J, Anderson DJ, Grønlien JH, et al. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther 2010;334(3):863-74
   PubMedGoogle Scholar
• Sydserff S, Sutton EJ, Song D, et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 2009;78(7):880-8
   PubMed Web of Science ®Google Scholar
• Wishka DG, Walker DP, Yates KM, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem 2006;49(14):4425-36
   PubMedGoogle Scholar
• Bitner RS, Bunnelle WH, Decker MW, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer’s disease. J Pharmacol Exp Ther 2010;334(3):875-86
   PubMedGoogle Scholar
• Barbier AJ, Hilhorst M, Vliet AV, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin Ther 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Kuan S, Loewen G, Gawryl M, Hilt D. Population pharmacokinetic modeling of EVP-6124 following oral administration. Alzheimer’s Dementia 2013;9(4 Suppl):P660
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141(11):1356-64
   PubMed Web of Science ®Google Scholar
• Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148(5):379-97
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Cross JT, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148(5):370-8
   PubMed Web of Science ®Google Scholar
• Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014;41(2):615-31
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011
   Google Scholar
• Darby DG, Pietrzak RH, Fredrickson J, et al. Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimers Dement 2012;8(2):95-104
   PubMed Web of Science ®Google Scholar
• Maruff P, Lim Y, Darby D, et al. Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Psychol 2013;1(1):1-11
   PubMedGoogle Scholar
• Cedarbaum JM, Jaros M, Hernandez C, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimers Dement 2013;9(1 Suppl):S45-55
   Google Scholar
• Harrison J, Minassian SL, Jenkins L, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64(9):1323-9
   PubMed Web of Science ®Google Scholar
• Hilt D, Gawryl M, Koenig G. EVP-6124: safety, tolerability and cognitive effects of a novel a7 nicotinic receptor agonist in Alzheimer’s disease patients on stable donepezil or rivastigmine therapy. Alzheimer’s Dementia 2009;5(4 Suppl):e32
   Google Scholar
• EVP-6124 - safety, tolerability and cognitive effects of a novel α7 nicotinic receptor agonist in Alzheimer’s disease patients on stable donepezil or rivastigmine therapy. FORUM Pharmaceuticals. Available from: www.forumpharma.com/assets/publications-Hilt_etal_A7_ICAD2009.pdf [Last accessed 22 October 2014]
   Google Scholar
• Hilt D, Gawryl M, Koenig G, et al. EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild-to-moderate Alzheimer’s disease patients: results of a six-month, double-blind, placebo controlled, dose ranging study. Alzheimer’s Dementia 2012;8(4 Suppl):S746
   Google Scholar
• EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild to moderate Alzheimer’s disease patients: Results of a six-month, double-blind, placebo controlled, dose ranging study. FORUM Pharmaceuticals. Available from: www.forumpharma.com/assets/publications-EVP-6124AAICPressConf.pdf [last accessed 22 October 2014]
   Google Scholar
• Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75(5):677-85
   PubMed Web of Science ®Google Scholar
• Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimer’s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010;81(12):1363-8
   PubMed Web of Science ®Google Scholar
• Harrison J, Dgetluck N, Gawryl M, et al. Validation of a novel cognitive composite assessment for mild and prodromal Alzheimer’s disease. Alzheimer’s Dementia 2013;9(4 Suppl):P661
   Google Scholar
• Hilt DC, Gawryl M, Koenig G, et al. Positive effects on cognition and clinical function in mild to moderate Alzheimer’s disease patients with a selective alpha-7 nicotinic partial agonist: Interpretation of effects based on a PK/PD model. 5th Conference Clinical Trials on Alzheimer’s Disease. Monte Carlo, Monaco 2012
   Google Scholar
• EnVivo pharmaceuticals initiates COGNITIV-AD, a Phase 3 clinical trial program of encenicline (EVP-6124) in Alzheimer’s disease. FORUM Pharmaceuticals. 22 January 2014. Available from: www.forumpharma.com/content/news-events/cognitiv-ad-program [Last accessed 22 October 2014]
   Google Scholar
• Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s disease. ClinicalTrials.gov. 21 October 2013. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01969123 [Last accessed 22 October 2014]
   Google Scholar
• Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s disease. ClinicalTrials.gov. 21 October 2013. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01969136 [last accessed 22 October 2014]
   Google Scholar
• Encenicline - potentiator of alpha7 receptor response. FORUM Pharmaceuticals. Available from: www.forumpharma.com/content/innovation-pipeline/a7-receptor-agonists [last accessed 22 October 2014]
   Google Scholar
• Study of the safety and clinical effects of 2 doses of EVP-6124 in subjects with Alzheimer’s disease who complete study EVP-6124-024 or EVP-6124-025. ClinicalTrials.gov 27 November 2013. Available from: http://clinicaltrials.gov/ct2/show/record/NCT02004392 [last accessed 22 October 2014]
   Google Scholar
• Safety and efficacy of MT-4666. ClinicalTrials.gov. 26 December 2012. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01764243 [Last accessed 22 October 2014]
   Google Scholar
• Study of the safety of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s disease currently receiving memantine. ClinicalTrials.gov. 17 September 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT02246075 [Last accessed 22 October 2014]
   Google Scholar
• Preskorn SH, Gawryl M, Dgetluck N, et al. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 2014;20(1):12-24
   PubMed Web of Science ®Google Scholar
• Hilt D, Meltzer HY, Gawryl M, et al. EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. 50th Annual Meeting of the American College of Neuropsychopharmacology. Waikoloa Beach, Hawaii, USA 2011
   Google Scholar
• Safety, tolerability, and pharmacokinetic study of EVP-6124 in patients with Alzheimer’s disease. ClinicalTrials.gov. 1 October 2008. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00766363 [last accessed 22 October 2014]
   Google Scholar
• Loewen G, Gawryl M, Schutz R, et al. EVP-6124, an alpha7 nicotinic acetycholine receptor partial agonist, did not delay cardiac repolarization in healthy subjects. Alzheimer’s Dementia 2013;9(4 Suppl):P660-1
   Google Scholar
• Cachelin AB, Rust G. Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits. Mol Pharmacol 1994;46(6):1168-74
   PubMedGoogle Scholar
• Søderman A, Thomsen MS, Hansen HH, et al. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain Res 2008;1227:240-7
   PubMedGoogle Scholar
• Ren K, King MA, Liu J, et al. The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience 2007;148(1):230-7
   PubMedGoogle Scholar
• Parri HR, Hernandez CM, Dineley KT. Research update: alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease. Biochem Pharmacol 2011;82(8):931-42
   PubMedGoogle Scholar
• Effect on cognitive performance and safety/tolerability of SSR180711C in mild Alzheimer’s disease. ClinicaTrials.gov. 16 January 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00602680 [Last accessed 22 October 2014]
   Google Scholar
• Targacept ends Alzheimer’s drug trial after mid-stage failure. Reuters. 14 July 2014. Available from: www.reuters.com/article/2014/07/14/us-targacept-study-idUSKBN0FJ2EE20140714 [last accessed 22 October 2014]
   Google Scholar
• Safety and cognitive function study of EVP-6124 in patients with mild to moderate Alzheimer’s disease. Available from: http://clinicaltrials.gov/show/NCT01073228
   Google Scholar
• Safety, tolerability, and pharmacokinetic study of EVP-6124 in patients with schizophrenia. Available from: http://clinicaltrials.gov/ct2/show/NCT01556763
   Google Scholar
• safety and cognitive function study of EVP-6124 in patients with schizophrenia. Available from: http://clinicaltrials.gov/show/NCT00968851
   Google Scholar